Used in pharmaceutical research as a potent and selective inhibitor of Janus kinase 1 (JAK1), showing promise in the development of treatments for autoimmune and inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel disease. Its structure enables high selectivity for JAK1 over other JAK family members, potentially reducing side effects commonly associated with broader JAK inhibition. Investigated for oral bioavailability and favorable pharmacokinetic profiles in preclinical studies, making it a candidate for small-molecule therapeutic agents targeting cytokine signaling pathways.